SAB Biotherapeutics, Inc.
NASDAQ:SABS
2.74 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities: | ||||||||||||||
| Net Income
| -7.335 | -5.026 | -22.857 | -5.102 | -6.881 | -7.354 | -6.278 | -7.076 | -4.776 | 0.986 | -17.585 | 1.972 | -2.942 | 1.41 |
| Depreciation & Amortization
| 1.022 | 1.985 | 0.944 | 0.985 | 0.892 | 0.923 | -0.715 | 0.91 | 0.781 | 0.677 | 0.002 | 0.415 | 0.3 | 0.277 |
| Deferred Income Tax
| 0 | 0 | -2.531 | 0 | 0.358 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 |
| Stock Based Compensation
| 0.601 | 0.617 | 0.537 | 0.639 | 0.645 | 0.603 | 0.629 | 0.578 | 0.57 | 0.898 | 0.002 | 0.881 | 0.433 | 0.349 |
| Change In Working Capital
| 0.263 | -2.774 | -0.427 | -1.495 | 0.037 | 4.211 | 20.3 | -1.801 | 0.707 | -4.991 | 13.304 | -3.756 | -4.176 | 8.083 |
| Accounts Receivables
| 0.193 | -0.193 | 0 | 0.362 | 0.401 | 4.793 | 17.49 | -3.329 | 2.174 | -3.776 | 0.013 | 6.895 | -5.515 | 8.976 |
| Change In Inventory
| 0 | 0 | 0.547 | -0.268 | -0.279 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change In Accounts Payables
| -0.045 | 0.243 | -0.106 | -0.321 | -0.041 | -2.234 | -3.961 | 0.541 | -0.038 | 0.523 | -0.003 | -1.397 | 1.952 | -3.836 |
| Other Working Capital
| 0.115 | -2.824 | -0.322 | -1.267 | -0.044 | 1.652 | 6.772 | 0.987 | -2.098 | -1.738 | 13.295 | -3.756 | -0.614 | 2.943 |
| Other Non Cash Items
| 0.159 | -1.183 | 10.888 | -0.195 | 0.05 | 0.011 | 13.858 | -0.784 | -1.734 | -7.864 | 8.589 | -1.837 | -0.002 | -0.666 |
| Operating Cash Flow
| -7.786 | -10.917 | -13.447 | -5.168 | -4.899 | -1.606 | 27.435 | -8.174 | -4.448 | -10.294 | 4.312 | -3.621 | -6.386 | 9.453 |
| Investing Activities: | ||||||||||||||
| Investments In Property Plant And Equipment
| -0.053 | -0.129 | -0.068 | -0.085 | -0.023 | -0.021 | -8.895 | -0.079 | -0.613 | -1.357 | 5.354 | -3.228 | -3.463 | -1.89 |
| Acquisitions Net
| 0 | 0 | -0.044 | 0.044 | 0 | 0 | 0 | 0 | 0 | 0.076 | 0 | 0 | 0 | 0 |
| Purchases Of Investments
| -0.105 | -31.23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -116.15 |
| Sales Maturities Of Investments
| 11.376 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activites
| 0 | -0.129 | -0.153 | 0 | 0 | 0 | -0.076 | 0 | 0 | 0.076 | 99.853 | -110.796 | 0 | 0 |
| Investing Cash Flow
| 11.219 | -31.359 | -0.068 | -0.041 | -0.023 | -0.021 | -8.971 | -0.079 | -0.613 | -1.281 | 105.206 | -110.796 | -3.463 | -1.89 |
| Financing Activities: | ||||||||||||||
| Debt Repayment
| -0.252 | -0.247 | -0.478 | -0.143 | -0.364 | -0.362 | -0.107 | -0.032 | -0.8 | -0.049 | -0.077 | -0.058 | -0.046 | -0.045 |
| Common Stock Issued
| 0 | 0.02 | 67.159 | 0.002 | 0 | 0.002 | 0.077 | 0 | 0.069 | 0.008 | -117.645 | 0 | 0 | 117.436 |
| Common Stock Repurchased
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5.521 | 0 | 0 | 0 | 0 |
| Dividends Paid
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities
| -0.069 | -0.167 | 60.883 | 0 | 0 | 0 | 39.714 | 0 | 0 | 0.008 | 34.555 | 117.436 | 0 | 0 |
| Financing Cash Flow
| -0.252 | -0.227 | 67.637 | -0.14 | -0.364 | -0.36 | 39.684 | -0.032 | -0.731 | -5.562 | -83.167 | 117.378 | -0.046 | -0.045 |
| Other Information: | ||||||||||||||
| Effect Of Forex Changes On Cash
| 0.028 | -0.028 | 0.018 | 0 | 0 | 0 | -26.935 | 0 | 0 | 0 | -26.328 | -12.526 | 0 | 0 |
| Net Change In Cash
| 3.208 | -42.532 | 54.141 | -5.349 | -5.286 | -1.987 | 31.213 | -8.284 | -5.792 | -17.137 | 38.877 | -9.565 | -9.896 | 7.518 |
| Cash At End Of Period
| 17.242 | 14.034 | 56.566 | 2.425 | 7.774 | 13.06 | 39.545 | 8.332 | 16.616 | 22.408 | 39.545 | 0.668 | 10.233 | 20.128 |